Coya Therapeutics’ (COYA) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report issued on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $15.00 target price on the stock.

Other research analysts have also recently issued reports about the company. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, January 8th. Wall Street Zen upgraded Coya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Lake Street Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Coya Therapeutics in a research note on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Finally, BTIG Research raised their target price on shares of Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Coya Therapeutics Stock Performance

Shares of Coya Therapeutics stock opened at $4.61 on Wednesday. Coya Therapeutics has a 52-week low of $3.94 and a 52-week high of $8.29. The company has a fifty day moving average of $4.99 and a 200-day moving average of $5.75. The stock has a market capitalization of $96.44 million, a price-to-earnings ratio of -4.15 and a beta of 0.27.

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC raised its holdings in shares of Coya Therapeutics by 101.7% during the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after acquiring an additional 13,176 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in Coya Therapeutics in the 2nd quarter worth $119,000. JPMorgan Chase & Co. bought a new position in Coya Therapeutics in the 3rd quarter worth $28,000. CM Management LLC lifted its position in shares of Coya Therapeutics by 50.0% in the 3rd quarter. CM Management LLC now owns 300,000 shares of the company’s stock worth $1,710,000 after purchasing an additional 100,000 shares during the period. Finally, Dauntless Investment Group LLC boosted its stake in shares of Coya Therapeutics by 199.5% during the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after purchasing an additional 101,932 shares in the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical?stage biotechnology company focused on the discovery and development of first?in?class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small?molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.